A revolution in In-Vitro Diagnostics (IVD) has begun. Society is seeking, indeed demanding, smaller, faster, and more cost-effective ways to diagnose the physical condition of patients. Avitar is leading that revolution.
Avitar developed and launched ORALscreen™ , the world's first disposable oral fluid point-of-collection test (POCT) for drugs-of-abuse (DOA). In 2000, we began marketing our four-panel test device for detection of marijuana, cocaine, opiates, and methamphetamines, including MDMA or Ecstasy, which can identify 96% of all positive drug screens. ORALscreen enables our customers, specifically corporate and criminal justice systems, to rapidly determine, with less down time, the status of those being tested, thereby lowering costs. Corporations also can do so without imposing the indignity of urine testing on their employees, the majority of which are not drug users.
In addressing the DOA market, Avitar is assembling a "value net" combining state-of-the-art products with companion services to offer customers a complete package to develop a truly drug-free workplace.
Avitar will continue to innovate not only the products we produce, but also the sales, marketing, and distribution methods we practice.
The larger $20 billion IVD market affords Avitar an even large opportunity. The same demands for smaller, faster, more cost-effective products prevail in this market, and Avitar's technology will no doubt provide innovative solutions. We have begun development.
Looking forward, we are quite enthusiastic about our future, as the leader in on-site oral fluid diagnostic testing in the DOA market. With several key patents in place and the first non-invasive, rapid, on-site oral fluid test for DOA in the marketplace, not only are we a leader in the field, but we are poised to seize a sizeable market share. We have developed the expertise that will allow us to continue to deliver high quality, proprietary, groundbreaking, and in fact, 'revolutionary' products.
Peter P. Phildius
Chairman and CEO